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Heterosexual HIV transmission is the most common viral transmission route worldwide. To establish a 
persistent infection the virus needs to cross the mucosal surface of the genital tract. The genital mucosa 
is thus considered to be the portal of HIV entry and initial site of viral replication. A better understanding 
of the immunological milieu at the portal of viral entry is crucial for the development of preventive 
interventions.  
In Paper I we investigated how herpes simplex virus 2 (HSV-2) affects the genital epithelial barrier and 
mucosal immune response in an HSV-2 seropositive, asymptomatic vs. HSV-2 seronegative male 
population in Kenya. The two study groups had comparable levels of all selected markers of 
inflammation and epithelial integrity, except for lower mRNA levels of the epithelial junction protein 
claudin-1 in the HSV-2 seropositive group, which may indicate a less robust genital epithelial barrier.  
In Paper II, we investigated how the use of progesterone-based hormonal contraceptives affects the 
genital epithelial barrier and mucosal HIV receptor expression in healthy Swedish women. The 
progesterone-based intrauterine device (pIUD) group was compared to a non-hormonal contraceptive 
(noHC) group and a combined oral hormonal contraceptives (COC) group. Similar protein expression 
levels of HIV receptors and co-receptors were observed in the three study groups. However, women 
using pIUD displayed a thinner apical layer of the ectocervical epithelium and lower mRNA levels of 
the epithelial junction protein ZO-1 as compared to the control groups. These results suggest that pIUD 
use may weaken the ectocervical epithelial barrier against invading pathogens, such as HIV. 
In Paper III, we further investigated how the use of hormonal contraceptives affects the production of 
antimicrobial peptides (AMPs) in different compartments of the female genital mucosa, including 
secretions and tissue. Women using COC had significantly lower mRNA levels of the AMPs BD-2 and 
trappin-2 in ectocervical tissue as compared to pIUD users. The two groups showed no differences in 
AMP protein expression in neither cervicovaginal secretion (CVS) nor in ectocervical tissue. These 
results suggest that the impact of sex hormones on local immune defences varies in tissue vs. secretions 
in the female genital tract.  
In Paper IV we examined if epithelial thickness and /or the quantity and localization of HIV target cells 
in ectocervical epithelium is associated to the relative resistance of HIV exposed seronegative (HESN) 
women. Thus, female sex workers defined as HESN were compared to control women who were 
relatively new to sex-work. Our results show that the HESN phenotype is not associated with an altered 
epithelial thickness or with altered levels or distributions of HIV target cells in the ectocervical 
epithelium. 
In summary, the studies characterized epithelial integrity in both the male and female genital tract, as 
well as the localization, distribution and quantity of immune cells and proteins in both tissue and 
secretions. These factors may be of importance for HIV susceptibility and was compared between 
study groups, characterized by various risk factors for HIV infection including HSV-2 infection, 
different types of hormonal contraceptive use and a phenotype of relative HIV resistance. Our results 
imply that the genital mucosa is a complex site and it is therefore of major importance to study the 
local immunological milieu in the tissues and not solely in secretions, which opens up for a much 
more comprehensive picture. Further, our data indicates that strengthening the genital epithelial barrier 
of the local genital mucosa may be a beneficial way to reduce sexual transmission of HIV, and should 
thus be incorporated in potential future prevention strategies against HIV infection.  
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1.1 The human immunodeficiency virus (HIV) 
The first medical report on HIV was published in 1981 and described four homosexual men 
who suffered from lymphopenia and opportunistic infections such as pneumocystis 
pneumonia, a disease normally associated with severe immunosuppression (1). This was 
followed by reports of other cases, in homosexual men, with rare opportunistic diseases 
together with symptoms including fever and weight loss (2, 3). The aggressive new disease 
was characterized by severe immunosuppression, therefore named acquired 
immunodeficiency syndrome (AIDS) (1982) (4) and it took approximately two years to 
identify the virus, that would later be known as HIV-1, as the cause of AIDS (5). This 
discovery resulted in the Nobel prize in 2008 (6). In 1986 another type of HIV, named HIV-
2, was discovered (7) and is mainly found in West Africa. HIV-1 is responsible for the HIV 
epidemic worldwide and will be referred to as HIV in this thesis. 
HIV is derived from the Simian Immunodeficiency virus (SIV), which infects non-human 
primates (NHP) (8, 9). The natural hosts such as African green monkeys and sooty 
mangabeys, do not develop any clinical symptoms, while non-natural hosts such as monkeys 
of Asian origin develops a disease in resemblance to human AIDS (10). HIV belongs to the 
lentivirus genus and the retrovirus family, and retroviruses hold the unique ability to reverse 
the pathway of genetic information progress using the enzyme reverse transcriptase so that it 
passes from RNA to DNA. The viral DNA are then inserted to the host cells’ DNA, with use 
of the viral enzyme integrase, and thereby a chronic infection is established.  
 
1.1.1 Clinical course of HIV infection 
During initial HIV infection, the plasma viral load increases exponentially and peaks over 6 
logs in approximately two weeks after when it is first detected in blood (11). This progress is 
followed by a sharp decrease of viremia to a viral set point level of two logs lower a month 
later (12). The clinical manifestation of the first one to three weeks with high plasma viral 
load includes symptoms similar to those of glandular-fever, including fever, tonsillar 
hypertrophy and myalgia (13). This stage is referred to as the “acute/early phase”, with 
leucopenia, a significant loss of cluster of differentiation (CD) 4 receptor expressing T cells 
and a high viral load (13). CD4+ T cells are the primary target cells for HIV infection and the 
CD4+ T cell count together with plasma viral load are essential markers used for monitoring 
the progression of HIV disease. The early phase of HIV infection is characterized by a 
massive depletion of CD4+ T cells (14). This process predominantly occurs in the 
gastrointestinal tract, and to a lower extent in peripheral blood, lymph nodes and cervix (15). 
Two factors are suggested to be the main causes for the ultimate cell depletion over time; the 
progressive CD4+ T cell failure mediated by the virus itself and the high immune activation 
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(16). Early initiation of antiretroviral therapy (ART) treatment restores to a certain extent the 
CD4+ T cell levels, although not as high levels as prior to infection (17). The acute phase is 
followed by the “clinical latency phase” characterized by the absence of clinical symptoms 
and a low viral replication of HIV. With treatment, this phase can continue for a long time, 
although with no treatment it continuous for an average of 10 years (15). The clinical latency 
phase may be followed by development of AIDS if no treatment for HIV infection is 
initiated. This development involves a decline in the number of CD4+ T cells (lower than 200 
cells/mm3), the loss of vital immune function, progressive impairment of cellular immunity, 
and thus increased susceptibility to opportunistic infections, such as Pneumocystis carinii 
pneumonia and an increased risk of cancer, including Kaposi´s sarcoma (1, 3, 16). 
 
Figure 1. The global HIV-1 prevalence latest report 2017 according to WHO. Generalized by world major 
regions, including Eastern Mediterranean, western Pacific, South-East Asia, Europe Americas and Africa. HIV-1 
prevalence per region was predicted based on representative populations within that region.  
 
1.2 Global HIV distribution 
The prevalence of HIV during 2017 was reported to be around 36.9 million people (18) 
(Figure 1). African countries are suffering from the HIV epidemic and especially the Sub-
Saharan part of Africa is considered to be the most influenced region, with 66% of all global 
new HIV infections according to the latest report (18). In the same year, there was an 
estimation of 25.6 million HIV-seropositive people living in Sub-Saharan Africa (19). Major 
barriers to testing include stigma and discrimination, inaccessibility of services, and low 
awareness of the benefits of testing and early treatment (20). The dominant route of HIV 
transmission in Africa is heterosexual intercourse, which is in contrast to both Europe and 
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USA. E.g. in Western Europe the predominant route of HIV transmission is sex between 
men, while in Eastern Europe drug injections and heterosexual transmission are the most 
common routes of transmission (18). HIV transmission in the European regions has not 
drastically declined the last 10 tears, despite the development and increased availability of 
ART, as well as extensive public health efforts (18). The estimated number of new HIV 
infections in Central Asia and in Eastern Europe during 2016 was 190.000, which was 
alarmingly 60% higher as compared to year 2010 (18).  
 
 
1.2.1 HIV prevalence among key populations: sex workers 
UNAIDS considers sex workers, men who have sex with men, transgender people, people 
who inject drugs and prisoners and other detained people as the main key population groups 
who are especially vulnerable to HIV and commonly lack adequate access to services. In 
2016, excluding the Sub-Saharan Africa region, key populations and their sexual partners 
accounted for 80% of all new HIV infections. Even in Sub-Saharan Africa, key populations 
accounted for 25% of new HIV infections during this year (18). Sex workers are at very high 
risk of acquiring infection, and female sex workers (FSW) are reported to have a 13 times 
higher HIV prevalence than the general population (21). This is particularly the case in 
countries where the HIV prevalence is very high such as in South Africa, where the HIV-
prevalence rates in young women in Umlazi Township rose from less than 1% at age 15 to 
66% at age 23 (22). 
In this thesis, we have focused on FSW in Nairobi, Kenya. In Kenya, the HIV-prevalence is 
5.4% in adults between the ages of 15-49 years as compared to 0.8% globally (18). The 
prevalence of HIV among FSW in Kenya is approximately 30% and furthermore, about 50% 
of HIV-positive Kenyan FSW are not aware of their HIV status, despite national STI-testing 
programmes (23). This results in severe consequences such as delays in access to treatment 
and healthcare, as well as continuous HIV transmission (23). There are several factors that 
contribute to increased vulnerability to HIV transmission that could be avoided by assessment 
of issues present in key populations, such as FSW, together with legal measures. For 
example, unprotected sex, sexual violence, discrimination as well as social and economic 
factors contribute to the increased susceptibility to HIV transmission in FSW (24). It is 
implied that elimination of sexual violence alone could prevent 17% of HIV infections in 
FSW and their clients. Moreover, decriminalization of selling sex, but not buying sex, could 
prevent 33% of HIV infections in FSW and their partners during the next decade (25). By 
focusing on improvement in these areas, the HIV transmission in vulnerable groups may 






1.3 HIV treatment and challenges 
The most important step in the process of limiting the HIV epidemic has been the 
introduction and development of ART (26). The access of ART has significantly increased 
over the years; in 2001, only 1 million HIV seropositive people had access to ART, as 
compared with an estimated of 20.9 million in June 2017 (18). During the establishment of 
ART and the following reduction of HIV transmission, the Pre-Exposure Prophylaxis (PrEP) 
treatment could be implemented in risk groups who were at a high risk of acquiring infection 
(27, 28). The PrEP treatment is a daily intake of a pill containing two different medicines, 
tenofovir and emtricitabine. According to the federal guidelines by US Centers for Disease 
Control and Prevention (CDC), PrEP should be administered to risk groups such as FSW and 
HIV seronegative individuals who have an ongoing sexual relationship with an HIV-positive 
partner. 
Besides the positive outcomes of ART, there are issues associated with the life-long treatment 
including side-effects such as lipodystrophy and insulin resistance (29, 30). Furthermore, 
antiviral drug resistance is prevalent, and develops under suboptimal therapeutic conditions 
due to for instance patient incompliance or self-medication along the increased access to ART 
(31). However drug resistance can also appear even with successful viral suppression (32). 
Viral reservoirs furthermore act as sanctuary sites, as tissues or cells are inefficiently targeted 
by the antiretroviral drugs, and thus continuous HIV-replication occurs in various reservoirs 
under antiretroviral therapy (29). Another issue is the inevitable consequences of an increased 
economical demanding due to the increased number of individuals receiving ART.  
 
1.3.1 Future goals 
UNAIDS is today reaching towards the new global goals in the process of defeating the HIV 
epidemic. i) To achieve the 90-90-90 treatment target by year 2020. This goal is that in 2020, 
90% of all HIV-infected people will be aware of their HIV status, 90% of all HIV- infected 
people who know their HIV status will receive ART, 90% of people with ART will show 
suppressed viral loads (90-90-90) (21, 33), ii) Less than 500 000 new HIV infections will 
occur annually and the global HIV- related deaths will decline to fewer than 500 000 in 2020. 
Ultimately, the main goal is that the HIV epidemic will be ended by year 2030 (21).  
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Figure 2. Schematic illustration of the suggested mechanism for HIV heterosexual transmission across the 
female genital mucosa. The female genital mucosa is harboring HIV target and effector cells, as well as 
epithelial tight junction proteins, which are protecting against invading pathogens like HIV. The epithelial 
linings are covered by genital secretions containing hormones, microbes and innate proteins also important in 
HIV transmission. Micro-breaks in the epithelium are thought to facilitate entrance of HIV. 
 
1.4 HIV transmission and mucosal immune responses to HIV 
Sexual HIV transmission is the most common route of transmission followed by mother – to 
– child transmission (vertical transmission) and then blood-borne infection (21, 34). The main 
target sites for sexual HIV transmission are the mucosal tissues of the foreskin, cervix and 
rectum (35).  
To initiate infection, the virus needs to reach the HIV target cells which are located both in 
the epithelium and in the underlying submucosal tissue (36) (Figure 2, Figure 3). The degree 
of virus infiltration is influenced by the phenotype and concentration of virus and the 
efficiency of the protective mucosal barrier functions.
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Figure 3. A model of the tight (TJ) and adherens junctions (AJ) in an epithelial cell. The TJ consist of 
transmembrane proteins (occludins, claudins, and JAMs) linked to an actin cytoskeleton via cytoplasmic ZO 
(zonula occludens) proteins and ZO-1 binds to actin. The AJ are composed of the nectin and the E-cadherin-
catenin system. TJs and AJs form the apical junctional complex, which is linked to the actin cytoskeleton 
network. Reprinted with permission (37). 
 
HIV enter their target cells by binding its viral envelop protein gp120 to the CD4 molecule on 
the cell surface of the target cells. This induces a conformational change which promotes 
binding of the viral envelop protein gp41 to one of the two co-receptors, CCR5 or CXC 
chemokine receptor 4 (CXCR4) that subsequently induces insertion of the distal tips of gp41 
into the cellular membrane and fusion occurs between the viral- and cellular membranes. The 
initial HIV transmission predominantly occur in a CCR5 dependent way (38) and the initial 
infection events generate a small population of founder cells within the mucosal tissue. This 
founder population expands and the virus disseminates to draining lymph nodes, with the 
help of antigen presenting cells (39, 40). Subsequently, the infection is spread systemically 
and the main HIV replication occurs in the lymph nodes (41).  
The HIV target cells in the cervical mucosa include CD4 expressing T cells, dendritic cells 
(DCs) and macrophages (42, 43). Langerhans cells (LCs), is a subset of DCs localized in the 
ectocervical epithelium, expected to be among the earliest cells to encounter the virus and 
which may further pass the virions to CD4+ T cells (44) that are thought to be the main target 
cells for HIV (39, 45, 46). LCs can bind to HIV in two different ways; either through the 
CD4/CCR5 receptors (same as the CD4+ T cells) or via the Langerin pathway (47). Langerin 
 
 7 
is a C-type lectin receptor which binds specifically to the high mannose glycan present on 
HIV gp120, and this may lead to internalization of the virus into Birbeck granules followed 
by viral degradation (48, 49) (Figure 4). Birbeck granules are langerin-positive organelles 
exclusively present in LCs and have been reported to be linked to the lysosomal degradation 
pathway in LCs. However, the function of Birbeck granules and how it contributes to limiting 
HIV-1 infection remains to be determined. A recent study by Pena-Cruz  et al reported that 
vaginal LCs do not harbor Birbeck granules unlike other blood- and tissue-derived LCs (46).   
 
Figure 4. LCs interaction with HIV-1. Langerin is a receptor for HIV-1 on LCs and internalizes HIV-1 
through the Birbeck granules (i). Langerin interaction with HIV-1 results in HIV-1 degradation, viral clearance 
and inhibition of HIV-1 transmission. However, the specific function of Birbeck granules is not fully established 
(ii) A block of Langerin function through drugs, co-infections or mutation may lead to LCs transmitting HIV-1 
efficiently to T cells (right) through infection of the LCs. Adapted with permission (50). 
 
As mentioned above, the CD4+ T cells are thought to be the main target cells and they are 
abundant in ectocervical mucosa, where they are distributed in the epithelium and the 
underlying submucosa (43). More recently, studies have implied that the α4β7- and α4β1 
integrin expressing CD4+ T cells and the interleukin (IL) 17 producing CD4+ T cells (Th17) 
are more susceptible to HIV infection as compared to other CD4+ T cell subsets (51, 52). 
Cervical Th17 cells are furthermore depleted during early HIV infection, in concordance with 
the finding of the preferential infection of this cell type (53). DCs situated in the submucosa 
can facilitate CD4+ T cell infection through the C-type lectin receptors DC-SIGN and 
mannose receptor (MR) that binds to HIV gp120 (54-56). Additionally, CD4+CCR5+ 
macrophages are another cell population present predominantly in the submucosa close to the 
basal membrane, and have been shown to be productively infected by HIV ex vivo (57).  
However, in order for the virus to infect their target cells they have to gain access to the tissue 
which are protected by several mechanisms. Mucus and the commensal microbiota make up a 
first line of defense, which hinder pathogens to enter the frontline tissue/epithelium. Soluble 
factors belonging to the innate and adaptive immune system are present in the 
mucus/secretions as well as within mucosal tissue and constitutes another line of defense that 
prevent infections (58). Among these immunologic mediators are a heterogeneous group of 
small proteins displaying microbicidal activity against a broad range of pathogens, generally 
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referred to as antimicrobial peptides (AMPs) (59). AMPs are constitutively produced by 
epithelial cells and leukocytes in the female genital mucosa (FGM) (60, 61). AMPs include 
defensins, comprising of human neutrophil peptides (HNP) 1-3, or α-defensins 1-3, and β-
defensin (BD) 2, human cathelicidin antimicrobial peptide (hCAP) 18/LL-37, and the acidic 
proteins secretory leukocyte protease inhibitor (SLPI) and trappin-2/elafin. These factors 
have different mechanisms of action, but they have all been demonstrated to inhibit the 
infectivity of a number of microorganisms in vitro, in particular HIV-1 (59).  
The epithelium itself also makes up a line of defense; it contains the epithelial junction 
protein complex, a network of proteins that constitutes a selective barrier. It consists of tight 
junction proteins, adhesion proteins and desmosomes that allow penetration of essential 
molecules whereas it prevents pathogens to enter the tissue. Ex vivo studies in cervical 
explant models have shown that HIV virions can infiltrate up to 50μm of the intact 
ectocervical epithelium (62) and inflammation can affect this barrier so that pathogens, 
including HIV, can more easily gain access to their target cells in the mucosal tissue (36, 63, 
64). Furthermore, sex hormones can also affect this barrier and facilitate the viral access to 
HIV target cells (36). However, the genital mucosa is also populated by cells belonging to the 
innate and adaptive immune system, which adds another layer of protection against HIV 
infection. Innate lymphoid cells (ILC), including traditional natural killer (NK) cells are 
suggested to mediate early control of HIV infection (65, 66) while HIV-specific effector 
CD8+ T cells are important players of the adaptive immune response in HIV-infected 
individuals (67, 68). 
 
1.5 HIV susceptibility factors 
The risk of vaginal male- to- female HIV-1 transmission is low, about 0.08-0.3 % per 
unprotected sexual intercourse, as compared to anal sex where the risk is about 18 times 
higher (69, 70). Proven modulating factors are sexually transmitted infections (STIs) such as 
genital herpes caused by herpes simplex virus type 2 (HSV-2). Women who are HSV-2 
infected are approximately 9 times more likely to acquire HIV as compared to HIV-2 
seronegative women, and this is considered to partly be due to HIV entry through herpetic 
lesions and the increased counts of tissue residing CD4+ T cell seen during HSV-2 lesion 
events (71). Furthermore, sex hormones such as progesterone can also facilitate the viral 
access to HIV target cells. During the progesterone-high secretory phase of the menstrual 
cycle, uterine cytotoxic T lymphocyte (CTL) activity and NK cell cytotoxic activity are 
suppressed, whereas innate components are upregulated and the frequency of CD4+ 
expressing T cells are increased (36, 72). The balance in the microflora can also affect the 
risk of acquiring HIV. The balance is normally characterized by dominance of Lactobacillus 
species which is associated with lower HIV prevalence, while dysbiotic women with clinical 
bacterial vaginosis (BV) are at higher risk of HIV acquisition (73, 74). BV is associated with 
elevated levels of inflammatory cytokines and reduced levels of factors important for 
maintenance of mucosal barrier integrity, potentially explaining why BV contributes to 
 
 9 
increased HIV acquisition (75, 76). The inflammatory process itself can affect the genital 
mucosal barrier so that pathogens, including HIV, can gain access to their target cells in the 
mucosal tissue (36, 63, 64). Furthermore, other STIs including the presence of N. 
gonorrhoeae and Chlamydia trichomonas, contribute to a pro-inflammatory milieu in the 
genital mucosa and is associated with increased risk of HIV acquisition and transmission (64, 
77, 78). Thus, the composition of the genital microflora and STIs along with the mucosal 
innate immune system and the robustness of the genital epithelial barrier could further 
contribute to increased host susceptibility to infection (79). 
 
1.5.1 Herpes simplex virus 2 (HSV-2) and HIV susceptibility 
HSV-2 is one of the most common STIs of the genital skin and mucosa. More than 50% of all 
people living in Sub-Saharan Africa were reported to be seropositive for HSV-2 in 2014 (80), 
which are the highest levels of HSV-2 infection in the world. The exact levels vary however 
from country to country within this continent. This region also displays a high HIV 
prevalence (Figure 1). HSV-2 infection has been strongly associated with HIV infection (81-
83) and appears to increase both HIV susceptibility and the potential for a co-infected 
individual to transfer HIV to sexual partners (81, 83).  
During primary infection, HSV-2 infects genital epithelial cells and is then transported via 
sensory nerves to the sacral root ganglion, where lifelong latency is established. Intermittent 
genital shedding of HSV-2 in the immunocompetent person is frequent, with or without 
symptoms (84). In situ analysis of genital skin biopsies from HSV-2 lesions have revealed 
that cellular infiltrates and local inflammation persisted for months after healing, even with 
daily antiviral therapy (85). Genital skin lesions and activation of the mucosal immune 
response at time of local reactivation increase the risk of sexual transmission of the virus, as 
well as the risk of acquiring other genital infections, including HIV (85-87). The persistent 
mucosal inflammation of the human skin samples, caused by HSV-2 infection, including 
upregulation of the HIV co-receptors DC-SIGN and CCR5, may partly explain the inability 
of the antiviral HSV-2 therapy to reduce acquisition of HIV (85, 88, 89). 
 
1.5.2 Effects of progesterone on HIV susceptibility in female genital mucosa 
The female sex hormone progesterone has considerable effects on the genital mucosa 
including susceptibility to STIs (90, 91). In NHP-models it is clear that high progesterone 
levels significantly increase the susceptibility to SIV, as well as promote viral shedding in 
animals already infected with SIV (92). The widespread use of progesterone-based hormonal 
contraception (HC) is a much-appreciated method of birth control. There are different types 
of progesterone-based HCs such as progesterone intrauterine device (pIUD) containing the 
progestin levonorgestrel, combined oral contraceptives (COC) consisting of an estrogen 
(estradiol) and a progesterone (progestin) component and the injectable depot 
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medroxyprogesterone acetate (DMPA) containing a progestin component. Progesterone-
based HC, and especially the high progesterone injectable DMPA, has been shown to 
increase susceptibility to primary HIV infection as well as HIV shedding and transmission in 
already infected women (36, 93-95). The exact mechanism of this is not yet established, 
although progesterone-based HC have been associated with a thinning of the cervical 
epithelium and an increase in migration and activation of DC subsets in cervical explant 
models which theoretically may lead to increased HIV susceptibility (96-98). 
 
1.6 HIV Exposed Seronegative (HESN) women 
While some individuals become infected by HIV, others persist uninfected despite continual 
exposures and are defined as HIV-exposed seronegative (HESN). Reports from this group 
have included FSW, HIV serodiscordant couples, intravenous drug users, hemophiliacs and 
infants born to HIV-infected mothers (99, 100). Studying the HESN group provides a unique 
opportunity to investigate natural protection (relative resistance) against HIV and examples of 
factors associated with HESN FSW are outlined in Table 1.  
Table 1    
Examples of factors associated with the HESN status in female sex workers   
    
Factor  Correlation with HESN References 
Genetic loci polymorphisms    
Toll-like receptor 3 (TLR3) polymorphism  Reduced frequency Sironi et al. (2012) 
Complement receptor 2 (CR2) polymorphism  Higher frequency Herrero et al. (2015) 
Complement component 4 binding protein alpha (C4BPA)  Higher frequency Herrero et al. (2015) 
Myxovirus resistance 2 (MX2)  Higher frequency Sironi et al. (2014) 
Endoplasmic reticulum aminopeptidase type 2 (ERAP2)  Reduced frequency Biasin et al. (2013), Cagliani et al. (2010) 
Apolipoprotein B editing catalytic polypeptide (APOBEC 3H)  Higher frequency Cagliani et al. (2011) 
β-Defensin 1 (DEFB-1)  Higher frequency Zapata et al. (2008) 
Immune determinants    
Interleukin-1 beta (IL-1β)  Lower levels McLaren et al. (2010) 
Interleukin-6 (IL-6)  Lower levels McLaren et al. (2010) 
Interferon gamma (IFNγ)  Lower levels Pala et al. (2013) 
Activated T cells  Lower proportion Card et al. (2013) 
T regulatory cells  Higher levels Thibodeau et al. (2017) 
Chemokine (C-C motif) ligand 9 (CCL9)  Lower levels Lajoie et al. (2012) 
Interleukin-1 alpha (IL-1α)  Lower levels Lajoie et al. (2012) 
Chemokine (C-C motif) ligand 10 (CCL10)  Lower levels Lajoie et al. (2012) 
Innate antiinflammatory protease serpin  Higher levels Aboud et al. (2014), Gonzalez et al. (2015) 
Innate antiinflammatory protease cystatin  Higher levels Aboud et al. (2014) 
Systemic CD4+CCR5+ T cells  Lower proportion Jaumdally et al. (2017) 




In our specific study cohort in Nairobi, Kenya, we study HESN FSW, with HESN defined as 
women who are and have been active in sex work for at least 7 years. It has been speculated 
that these HESN women display low inflammation/immune activation status in their genital 
mucosa despite being sex workers (101-105). Furthermore, studies on a Beninese cohort of 
FSW also support maintenance of low-inflammatory conditions in the FGM of HESN 
individuals (106-109). 
Considerable genetic and immunological associations to the HESN phenotype have been 
reported in our cohort, such as reduced gene expression in the TLR-signaling pathway crucial 
for T cell activation (110, 111) as well as lower proportion of activated T cells and higher 
proportion of T regulatory cells (112) in the circulation. Furthermore, lower levels of 
inflammatory cytokines (103) and higher levels of innate anti-inflammatory antiproteases 
have been detected in the genital tract in the same cohort (113). However, the mechanisms of 
protection against infection associated to the HESN phenotype remains to be established and 







The main purpose of this thesis was to investigate how asymptomatic HSV-2 infection, 
progesterone-based HC, and relative resistance against HIV affect the local FGM milieu in 
order to better understand HIV susceptibility factors.  
Specific aims: 
Paper I. To investigate how HSV-2 seropositivity correlates with markers of the genital 
epithelial barrier and mucosal immune response in an asymptomatic male population in 
Kenya. 
Paper 2. To investigate how the use of progesterone-based HC affects the genital epithelial 
barrier and mucosal HIV receptor expression in healthy Swedish women. 
Paper 3. To investigate how the use of different HCs affect the production of AMPs in 
different compartments of the FGM including secretions and tissue. 
Paper 4. To investigate if epithelial thickness and quantity/localization of HIV target cells in 
ectocervical epithelium were linked with the relative resistance against HIV, which are 




3 MATERIALS AND METHODS 
 
3.1 Study populations and sample collection 
Samples from the following cohort were used in this thesis.  
The Kisumu cohort (Kenya): Foreskin tissue biopsies were obtained from men undergoing 
elective circumcision in a randomized, placebo-controlled clinical trial conducted in Kisumu, 
Kenya, through the Universities of Nairobi, Illinois and Manitoba Collaborative Research 
Project. The unblinded trial included two arms: the circumcision arm and the delayed 
circumcision (control) arm to examine whether male circumcision reduced HIV incidence 
(114). For the substudy in Paper I, samples were randomly selected and divided into two 
study groups according to HSV-2 serological status. Inclusion criteria were absence of 
clinical or laboratory signs of genital ulcers at time of circumcision and that the participants 
were HIV seronegative, sexually active, 18-24 years old, resident of Kisumu district, no plans 
to move for at least two years and haemoglobin 90g/L or more. Exclusion criteria were 
foreskin covering less than half of the glans, haemophiliac or other bleeding disorder, high 
prothrombin time index and other medical condition contraindicating surgery. For our 
substudy, equal numbers of specimens were thus randomly selected from each study group 
and matched for age (18–20 and 21–24 years). Screening for sexually transmitted diseases 
included a history of discharge and previously diagnosed STIs, a clinical examination 2 
weeks before and at the time of circumcision, as well as laboratory analysis of STIs (114). 
Serum specimens were tested for HSV-2 antibody (Kalon HSV-2 IgG ELISA, Kalon 
Biological Limited, Aldershot, UK) using the manufacturer's recommended cut-off (115). 
The tissue biopsies were collected by dissection following surgery, and snap frozen and 
subsequently stored at − 80°C.  
The Karolinska cohort (Stockholm): Cervicovaginal samples were collected from 
premenopausal volunteers enrolled at the Karolinska University Hospital. Laboratory analysis 
of STIs was performed and inclusion criteria was HIV seronegative status. Women using 
systemic immunosuppressive therapy or with a history of cervical pathology were excluded.  
Ectocervical tissue biopsies were collected from women using pIUD, COC or no HCs and 
were included for the studies in Paper II. Two biopsies from the superior portion of each 
donor’s ectocervix were collected by an experienced gynecologist. One of the biopsies was 
immediately frozen in liquid nitrogen and subsequently used for in situ staining, and the other 
biopsy was preserved in RNAlater and used for quantitative real-time polymerase chain 
reaction (qPCR) experiments.  
Furthermore, ectocervical tissue samples and cervicovaginal secretions (CVS) were obtained 
from women using pIUD or COC in Paper III. Ectocervical tissue biopsies were collected as 
described above. The CVS samples were collected by using a cotton-tipped swab that was 
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rotated 360° in the ectocervical os and a second swab to collect secretions from the posterior 
vaginal fornix.  
The Pumwani cohort (Kenya): In Paper IV, the study subjects were recruited from the 
Pumwani Commercial Sex Worker Cohort in the Majengo clinic in Nairobi, Kenya. Inclusion 
criteria were that the women should be active in sex work, uterus and cervix present, 18 to 50 
years of age and being premenopausal, willing to undergo cervical biopsies and undertake a 
month‐long period of sexual abstinence, having a regular menstrual cycle, no hormonal 
contraceptive use, not pregnant or breastfeeding and in general good health. Laboratory 
analysis of STIs was performed. The cohort includes two study groups: HESN women, who 
had been involved in sex work for seven years or more and HIV-seronegative women who 
had been involved in sex work for three years or less (new negatives, NN) which served as 
the control group. Ectocervical tissue biopsies was collected, as described above for the 
Karolinska cohort, by an experienced gynecologist at the Kenyatta National Hospital, 
Nairobi, Kenya.  
 
3.1 Ethical considerations 
All study participants were provided with written and oral information about the studies. 
Written informed consent was obtained from all individuals and all studies were reviewed and 
approved by the Regional Ethical Review Board of Stockholm (Stockholm, Sweden) (Paper 
I-IV), and additionally approved by the Kenyatta National Hospital ethics and research 
committee, the University of Illinois at Chicago institutional review board and the University 
of Manitoba biomedical research ethics board (Paper I), and approved by the ethics boards at 
Kenyatta National Hospital (Nairobi, Kenya) and University of Manitoba (Winnipeg, Canada) 
(Paper IV). 
 
Collecting genital samples is inevitably associated with ethical concerns and a gynecological 
examination can generally be followed by a feeling of there being an infringement of person 
integrity. Thus, only experienced specialists were involved in carrying out the examinations 
and in the collection of the samples included in our studies, in order to avoid any negative 
experiences as far as possible. During biopsy sampling a light bleeding can occur and a certain 
amount of discomfort can be experienced. The cervical biopsy sampling included in all papers 
has been evaluated and considered to be a safe and well-tolerated method (116). Regarding 
male circumcision, it is a well-established and safe method reducing HIV susceptibility and 
also the incidence of urinary tract infections and penile cancer according to UNAIDS (117). 
Men in Kenya who underwent extended follow-up exhibited sustained reductions in HIV 
incidence of 64% at five and a half years after the circumcision (117). 
 
Research including the Pumwani cohort involves our Canadian research collaborators who 
established the cohort more than 30 years ago. They have a strong community outreach 
program including regular information meetings for study volunteers and program peer leaders. 
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All participants were provided with HIV/STI prevention counselling, condoms, family 
planning assistances, treatment of STIs, medical care for acute and chronic illnesses, access to 
adequate diagnostic testing and referral for specialist consultant and/or hospitalization at 
Kenyatta National Hospital if required. Ectocervical tissue biopsies were obtained from FSWs 
and sampling of the ectocervical biopsies may raise concerns regarding the increased HIV 
susceptibility in this population. Therefore, all study participants were asked to abstain from 
vaginal sex during two weeks after the procedure and received monetary compensation 
equivalent to the expected loss of income. On-site detection of prostate-specific antigens 
indicated unprotected intercourse, and this detection has been recently evaluated in our cohort 




3.3.1 Quantitative real-time PCR 
 
Quantitative real-time PCR has many objective advantages over other PCR analysis such as 
speed, broad dynamic range of target DNA quantitation, and reduction of contamination 
although it is not necessarily more sensitive. mRNA expression of the genes of interests in the 
ectocervical and foreskin biopsies was assessed with qPCR as previously described (119).  
qPCR was used in Paper I-III. RNA was obtained from the RNAlater-stored biopsies by the 
commercially available RNeasy kit (Qiagen), according to the manufacturer’s protocol, and the 
RNA was subsequently converted into complementary (c) DNA using a Superscript II reverse 
transcriptase kit (Life Technologies). cDNA of the genes of interest was amplified, detected 
and quantified by the ABI PRISM 7700 system. Amplification of ubiquitin C (UBC) was used 
as an endogenous control. Ct values for target cDNA were normalized to UBC and fold change 
of the target genes was calculated using the 2-dCT equation. 
 
 
3.3.2 Enzyme-linked immunosorbent assay (ELISA) 
 
The Enzyme Linked ImmunoSorbent Assay (ELISA) is a technique that has been used for over 
40 years. As the technology developed the assay itself has become much more sensitive and is 
a good way to measure antigen levels in complex liquid sample. ELISA is quick and 
convenient, and antigens of very low or unknown concentration can be detected since capture 
antibody only grabs specific antigen. However, limitations are that only monoclonal antibodies 
can be used as matched pairs, which may be difficult to find, and enzyme/substrate reaction is 
short term so the optical density must be read as soon as possible. In Paper III, the 
concentration of AMPs in CVS samples was measured. The specific concentration of proteins 
including HNP1-3, LL-37, trappin-2, BD-2 and SLPI was measured by ELISA according to 




3.3.3 In situ-based imaging analysis 
There are logistic difficulties of collecting tissue samples, in particular from the genital 
mucosa from individuals who are at high-risk of infection or from HIV-endemic areas. 
Genital tissue biopsies can be safely collected from study participants (116) and can be stored 
at -80℃ for a long period. Microscopy-based in situ methods allow analysis of properties of 
single cells in small tissue samples and have an excessive visual advantage as compared with 
other cell-based methods such as flow cytometry. The exact anatomical cell localization and 
distribution within the tissue can be assessed by in situ-based analysis of tissue samples, 
which is of importance to understand essential component of cell-mediated immunity (120). 
Nevertheless, there are limitations associated with microscopy-based methods. The methods 
are dependent on specific antibodies which may not be available and limit the assessment of 
several markers at the same time, restricting phenotypical and functional cell evaluation. 
Furthermore, autofluorescence from the tissue, which often varies from different tissue 
compartment as well as from different individuals, is an issue that needs to be considered. 
Furthermore, a restriction is data acquisition and analysis. Manual cell counting is subjective 
and time consuming, and may thus be inappropriate for analysis of large-scale studies. 
Opposed to manual cell counting, automated cell counting gives greater precision, less 
variation and is less time-consuming. Nevertheless, the automated software is often inferior 
in addressing inter-individual variation of biological material as compared with manual 
analysis performed by an expert.  
In Paper I-III, manual image analysis was performed. In Paper IV, the automated image 
analysis software CellProfiler was used, which allows high-throughput image analysis and 
quantification of different immunological parameters in tissue sections (121, 122). 
CellProfiler was used for quantification of positive cells, detected with use of fluorescently 
labelled antibodies, in the ectocervical tissue sections.  
In Paper II and Paper III, cells were visualized with a peroxidase-labelled streptavidin-
biotin amplification method as compared with Paper I and Paper IV, where immune cells 
were stained with fluorescently labelled antibodies. Immunofluorescent staining allows 
visualization of several markers on a single cell more precise as compared to 
immunohistochemical staining due to the use of specific excitation and emission 
wavelengths. However, fluorochrome-based signals are usually not as stable (depending on 
the signal intensity and storage conditions) as compared to chromogen-based staining/signals. 
We thus scanned our immunofluorescent staining into digital images immediately after the 
staining was performed. 
 
3.4 Statistical analysis 
Paper I: The main objective was to assess the differences in HSV-2 seropositive men as 
compared to HSV-2 seronegative men. Categorical variables/clinical characteristics between 
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the study groups were compared by Pearson 2 test, and with Fischer´s exact test when the 
numbers of the groups included the clinical parameters were less than 5. Continuous variables 
were analyzed by using unpaired two-tailed Mann-Whitney U test. 
Paper II: In this study, the main objective was to compare the pIUD using women with the 
COC using women or with the group of women with noHC. Nonparametric comparisons 
were performed between the pIUD vs. COC and pIUD vs. NoHC and all immunological 
parameters were also compared between HPV positive and HPV negative women. Statistical 
significance between continues variables was assessed using the Mann-Whitney U test and 
Fisher’s exact test was used for categorical variables. 
Paper III: The two study groups consisted of women using pIUD and COC and Mann-
Whitney test was used to compare continuous variables between the groups and the 
nonparametric Spearman´s rank correlation test was used to assess linear association of 
clinical/continuous variables. 
Paper IV: The main objective was to compare HESN women to NN women. Distribution of 
categorical variables was measured by Fisher’s exact test. Mann-Whitney U- test was used 
for comparison of continuous variables between the groups. Further, multiple linear 




4 RESULTS AND DISCUSSION 
Paper I. HSV-2 is one of the most common STIs of the genital mucosa and is associated 
with an increased susceptibility to HIV (81-83). The increased susceptibility to HIV might 
be due to the persistent inflammation that HSV-2 causes in the genital mucosa (89). We 
hypothesized that HSV-2 seropositivity was associated with genital mucosal inflammation 
and a disrupted epithelial barrier, even in asymptomatic individuals. We thus aimed to 
investigate if foreskin samples collected from asymptomatic HSV-2 seropositive 
individuals would differ in respect to immune activation status and epithelial junction 
markers as compared to HSV-2 seronegative individuals. Foreskin tissue samples were 
collected from men undergoing elective circumcision in Kisumu, Kenya and stratified into 
study groups based on HSV-2 serology. The two study groups were similar in 
sociodemographic, behavioral risk and STIs, except for the HSV-2 seropositive group 
which displayed a higher educational attainment and number of sex partners than the HSV-
2 seronegative group.  
qPCR was used to assess the overall immune activation status of the foreskin tissue 
samples. However, no differences were seen in the mRNA levels of the selected markers 
between the study groups. Namely, the mRNA expression levels of markers for cytokines 
(IL-1, IL-6, TNF-α, IFN-α, CCL5), immunoregulatory receptors (CCR5, HLA-DR and β7), 
phenotypic cellular markers (CD4, CD3 and CD8,) the activation markers CD69, the CLRs 
Langerin, DC-SIGN and mannose receptor as well as of IgA were all similar across the 
study groups. Furthermore, the mRNA expression of the epithelial junction molecules E-
cadherin, ZO-1 and occludin were also similar between the groups. However, the HSV-2 
seropositive men had significantly lower mRNA expression of claudin-1 than the HSV-2 
seronegative men. Nevertheless, no multivariate analysis was performed which would have 
been relevant in the study. 
The epithelial junction proteins were further assessed by immunofluorescence staining for 
visualization of their tissue distribution. Claudin-1, as well as the other three epithelial 
junction proteins, was clearly expressed in the foreskin epithelium. However, the proteins 
showed an uneven distribution; some areas only had a few stained epithelial layers whereas 
other areas displayed several stained layers of thickness. 
Subclinical and clinical inflammation is usually characterized by increased expression of 
cytokines, influx of inflammatory cells and reduced epithelial barrier integrity. This was 
however not confirmed by the results in this study. Here we found that no general 
inflammation, apart from a decreased expression of claudin-1 at mRNA levels were seen in 
the foreskin of asymptomatic HSV-2 seropositive individuals, as compared to HSV-2 
seronegative individuals. A decreased expression of claudin-1 might indicate a less robust 
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genital epithelial barrier, which may affect the resistance of the mucosal barrier against HIV 
infection. This is exemplified by an isolated defect in only one of the epithelial junction 
proteins causing severe disease in individuals suffering from atopic dermatitis, in which 
results implicate that lower expression of Claudin-1 can enhance the spread of epidermal 
HSV-1 infections (123).  
It would have been interesting to also quantify all the immune and epithelial junction markers 
at the protein level to see if these data would indicate a more inflammatory status in the 
asymptomatic HSV-2 seropositive individuals versus the HSV-2 seronegative individuals. 
We could also have included other inflammatory markers of interest such as interferon  and 
, as well as IP-10, macrophage inflammatory protein–1β, IL-8, and monocyte chemotactic 
protein-1. These may have been upregulated since they have previously been reported to be 
associated with HIV seroconversion in women (124). Thus, more markers need to be 
addressed in the future. 
Unfortunately, there was no data on history of recurrent HSV-2 lesions. A less recurrent 
infection may not contribute to downregulation of epithelial junction proteins and increased 
levels of inflammation. Further, the foreskin tissue samples analyzed may not represent the 
exact localization where a previous lesion has occurred which may explain our results. The 
study participants could also have had a prior defect in claudin-1 expression either induced or 
genetically, which would be interesting to evaluate. A specific defect on the genital mucosal 
barrier in a highly vulnerable and relevant population could be of significance, since such 
defect may facilitate entrance of STIs including HIV. It would thus also be interesting to 
perform longitudinal studies to evaluate if claudin-1 is persistently down-regulated in the 
areas of HSV-2 lesions. 
Paper II. The female sex hormone progesterone has considerable effects on the genital 
mucosa including susceptibility to sexually transmitted infections (90, 91). Today, there is an 
ongoing debate whether the widespread use of different progesterone-based HC affect HIV 
susceptibility in women. Hence, in this study, we wanted to investigate how the use of 
progesterone-based HC affects the genital epithelial barrier and HIV target cells in the genital 
mucosa. Difficulties in performing this type of study is that women on HC lack a normal 
menstrual cycle while women with noHC show great variabilities in hormone levels during 
the menstrual cycle. We thus included two control groups, COC (consisting of both estrogen 
and progesterone components) and noHC. The noHC group represents women at different 
stages of the menstrual cycle. Ectocervical biopsies were collected from premenopausal, 
healthy women using pIUD, COC or noHC. The three study groups were similar regarding 
age, relationship status and STIs, however, the pIUD group had significantly more sex 
partners during the previous year as compared to the noHC group.  
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In situ staining and image analysis were used to assess the total thickness of the 
ectocervical epithelium, from the basal membrane to the luminal border. While no 
statistical differences were seen between the pIUD vs. the COC study groups, the pIUD 
group had a significantly thinner epithelium compared to the noHC group. To further 
characterize the thickness of the different layers, the epithelium was stained for the 
adherence junction protein E-cadherin to distinguish the E-cadherin-positive basal stratum 
malpighii layer from the apical, non-viable, E-cadherin-negative stratum corneum layer. 
The stratum malpighii layer was similar between the groups. The pIUD group displayed a 
significantly thinner stratum corneum as compared to the noHC group, but not compared to 
the COC group. 
To further explore the influence of progesterone-based HC use on the barrier function of the 
ectocervical epithelium, qPCR was used to assess mRNA levels of epithelial junction 
markers. While the mRNA levels for E-cadherin, claudin-1 and occludin were similarly 
expressed across the study groups, the level of ZO-1 mRNA was significantly lower in the 
pIUD users compared to the COC users, and trended lower as compared to the noHC users.  
Immunohistochemistry and image analysis were further used to measure the presence of HIV 
target cells. CD4+, CCR5+, and Langerin+ cells were present in the ectocervical epithelium of 
all the individual tissue samples from the three study groups. A small number of DC-SIGN+ 
cells were detected just below the basal membrane, in agreement with previous studies in 
FGM showing that DC-SIGN+ cells are not located in the epithelium, but in the submucosal 
tissue compartment (43, 125). Furthermore, no differences were seen in the frequencies of the 
positively stained HIV target cells between the three study groups. Within the ectocervical 
epithelium the CD4+ cells were the most abundant cell followed by CCR5+, cells, Langerin+ 
cells whereas DC-SIGN+ cells showed close to nil abundance.  
Collectively, these data show that women using pIUD displayed a thinner apical layer of the 
ectocervical epithelium and reduced ZO-1 expression as compared to the two control groups; 
the COC and the noHC group. At the same time, similar expression levels of HIV receptors 
and co-receptors were observed in the three study groups. These data suggest that pIUD use 
may weaken the ectocervical epithelial barrier against invading pathogens, including HIV. 
However, no multivariate analysis was performed, which would have been relevant in this 
study. Although down-regulation of a single protein may be compensated by higher 
expression of other proteins, this relative ZO-1 deficiency may affect the resistance of the 
mucosal barrier against HIV entrance, which may be deleterious from an HIV-transmission 
point of view. 
  
Immune cells, including HIV target cells, may be differentially distributed under the 
influence of exogenous sex hormones but may also be affected by the endogenous sex 
hormones, therefore two control groups were included in this study. pIUD usage did not seem 
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to have a significant impact on HIV target cells in the mucosa, however there are recent 
studies showing that DMPA increase susceptibility to primary HIV infection as well as HIV 
shedding and transmission in already infected women (36, 93-95). Thus, future studies using 
larger study cohorts and experimental studies using cervical explant models to evaluate the 
effect of exogenous sex hormones including DMPA are needed. 
Paper III. The first line of defense in the FGM against invading pathogens includes 
cervicovaginal fluids, commensal microbiota and a layer of mucus covering the cervical 
epithelium. Soluble factors including AMPs with microbicidal activity against a broad range 
of pathogens are present in genital secretions, as well as within mucosal tissue, and contribute 
to preventing infections such as HIV (59). Hence, in this study, we investigated how the use 
of different hormonal contraceptives affects the levels of AMPs in compartments of the FGM 
(tissue vs. cervical secretions). Healthy female volunteers using pIUD or COC from the 
Karolinska cohort were included. The study groups were similar in clinical characteristics 
including age, STIs and systemic medications.  
The levels of the selected AMPs (HNP1-3, BD-2, LL-37, SLPI and trappin-2) were assessed 
in the tissue compartment (ectocervical biopsies) by qPCR and immunohistochemistry, and in 
the secretions (CVS) by ELISA. The qPCR analysis revealed that SLIPI and trappin-2 were 
the most abundant AMPs in the ectocervical tissue, followed by BD-2, HNP1-3 and LL-37. 
Furthermore, women using COC had significantly lower mRNA levels of BD-2 and trappin-2 
than pIUD users, while the mRNA levels of the other three AMPs were similar between the 
two study groups. The mRNA levels of HNP1-3 and LL-37 correlated significantly in both 
study groups. 
Visual inspection of the immunohistochemical staining displayed that HNP1-3, SLPI and 
trappin‐2 seemed to be more abundant than LL-37 and BD-2. However, no quantitative 
image analysis was performed due to lack of a standardized way to quantify staining intensity 
at that time. Positive staining for HNP1-3, BD-2, LL-37 and SLPI were seen both in the 
epithelium and in the submucosa while positive staining for trappin-2 were only seen in the 
epithelium. Furthermore, HNP1-3 and LL-37 showed overlapping staining patterns.  
In the CVS samples HNP1-3 was the most abundant AMP, followed by SLPI, trappin-2, LL-
37 and BD-2. Similar levels of the five AMPs were seen in the two study groups. 
Interestingly, a significant positive correlation between HNP1-3 and LL-37, as seen for the 
mRNA levels, were also seen, in both study groups, for the protein concentration in the CVS 
of these AMPs. Both HNP1-3 and LL-37 are important effector molecules secreted by 
neutrophils at mucosal sites (126) and our results may imply that their expression is 
coordinated in the FGM. However, if and how this is regulated by sex hormones remains to 
be further investigated 
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The reduction in the mRNA expression of BD-2 and trappin-2 in the ectocervical tissue seen 
in the COC users was not accompanied by a significant reduction at the protein level of BD-2 
and trappin-2 in the corresponding CVS samples. The functional relevance of the difference 
in mRNA levels of BD-2 and trappin-2 between the groups needs to be further explored as 
well as the discrepancy between protein concentration in CVS of the AMPs and their mRNA 
expression in ectocervical tissue. This discrepancy may be due to post-translation- and 
secretion modifications such as proteolytic cleavage, or/and by the various sources of the 
CVS including the cervical vestibular glands, plasma transudate, and endometrial and 
oviductal fluids (127, 128).  
Collectively, these results suggest that the impact of sex hormones on local immune defenses 
varies in different compartments (i.e. tissue vs. secretions) of the FGM. This finding show the 
importance of examining tissue specimens in addition to genital secretions in order to 
adequately evaluate the effect of sex hormones on the local immune defenses of the FGM. 
The expression of these immunologic mediators within mucosal tissue at the site of infection 
may be as important as secretions in the immune defense of the host, but in a later stage. In 
this respect, the effect of hormonal contraception on susceptibility to infection may be more 
relevant in one compartment of the mucosa than in the other and may also vary across the 
female genital tract. Further studies including samples from multiple genital anatomical 
regions of the same individual is necessary to assess whether AMP expression is truly 
compartmentalized between mucosal tissue and secretions, as the result of a variable 
immunoregulatory effect of sex hormones in the female genital tract. 
Paper IV. The female genital tract is a critical site for sexual transmission of HIV, and a 
number of genetic and immunological correlates of relative resistance against infection have 
been described (Table 1). However, the phenotype of relative resistance of HESN at the local 
genital site of sexual mucosal HIV infection is not fully understood. Hence, in this paper we 
investigated if epithelial thickness and quantity/localization of HIV target cells in ectocervical 
epithelium were linked with the relative resistance against HIV associated with the HESN 
phenotype in the Pumwani cohort comparing HESN to NN women.  
The HESN women had been active in sex work for a median of 10 years and the NN women 
for a median of 2 years. The study groups were comparable for an extensive number of 
demographic parameters including STIs, however the HESN group were significantly older 
than the NN group and had experienced a higher number of pregnancies than the NN group. 
In order to investigate if the ectocervical epithelial thickness differed between the study 
groups, immunofluorescence staining was performed. Staining for the adhesion junction 
protein E-Cadherin was used to visualize the ectocervical epithelium and its two major layers 
stratum; malpighii, corresponding to the epithelial layer expressing of E-Cadherin, and the 
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stratum corneum, corresponding to the apical layer associated with lack of E-Cadherin. 
Digital image analysis was used to measure the thickness of the total epithelium, as well as 
the thickness of the two different layers of the epithelium. No significant differences were 
seen between the study groups, in none of the three comparisons. The HIV receptors CD4, 
CCR5 and Langerin were next assessed in the epithelium in two study groups and the 
immunofluorescence staining revealed that CD4+, CCR5+ and Langerin+ cells were present in 
all the individual tissue samples representing the two study groups. Staining of CD4 together 
with CCR5 was performed for identification of the main HIV target cells, and CD4 was 
stained together with Langerin for identification of LCs in the ectocervical epithelium. The 
quantity of these receptors was assessed by computerized image analysis, and the results 
showed that there were no significant differences in expression of any of the cell markers 
between the study groups.  
Next the spatial distribution of the CD4+, CCR5+, Langerin+ including CD4+CCR5+ and 
CD4+Langerin+ cells within the ectocervical epithelium were assessed by dividing the 
epithelium into 50µm segments. No statistical differences were seen, in none of the 50um 
segment, between the study groups, for any of the cell markers assessed. To further 
investigate the spatial localization of HIV target cells, the distribution of CD4+CCR5+ and 
CD4+Langerin+ was compiled for the two study groups, and the two sets of staining showed 
that CD4+Langerin+ cells were localized more apical as compared with the CD4+CCR5+ cells.  
We reasoned that a thick epithelium and low numbers of HIV target cells at a distant location 
far from the epithelial surface may contribute to relative resistance in the HESN phenotype. 
However, the results showed that this phenotype was not associated with an altered epithelial 
thickness, nor with altered levels or distributions of HIV target cells in the ectocervical 
epithelium.  
The finding of an apical distribution of CD4+Langerin+ cells near the vaginal lumen was 
expected, since the main role for DCs is to seize incoming pathogens. However, it is unclear 
if an apical localization of LCs may enhance or reduce HIV susceptibility. Both skin-based 
and FGM-based studies showed that LCs can serve as primary target cells for HIV (129, 
130), but also be a part of a protective barrier against HIV infection and transmission (47, 
131, 132). However, Pena-Cruz et al recently showed that vaginal epithelial DCs did not 
harbor Birbeck granules and therefore are potentially both infected early during heterosexual 
transmission and retain virus during treatment (46). A lack of Birbeck granules may explain 
why HIV is commonly acquired across mucosal surfaces but not from exposed skin (46). 
Vaginal epithelial DCs may thus have unique characteristics as compared to skin-based LCs, 
which need to be further investigated. 
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In this study, the potential mucosal immune correlates of the relatively resistant HESN 
phenotype was explored in unique ectocervical tissue samples. The HESN group was 
compared with women who had been involved in sex work for three years or less in the same 
cohort. Nevertheless, we cannot exclude that some of the NN will become HESN and have 
the same relative resistant phenotype, and it would be interesting to conduct a longitudinal 
follow-up study on these women considering the frequency of HIV seroconversion. Thus, 
further studies are needed to reveal multifactorial and individual mechanisms of protection 




5 OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
A better understanding of how asymptomatic HSV-2 infection, progesterone-based HC and 
relative resistance to HIV (the HESN phenotype) affect the genital mucosa is important for 
development of novel prophylactic compounds with the ultimate goal of lowering the risk of 
global HIV transmission. In males, the foreskin mucosa is a highly relevant site for 
investigating viral transmission since circumcision reduces the risk of acquiring HIV 
infection (133). Here we have studied a representative population of young men living in an 
HIV endemic region in Kenya (114). In females, the cervix is an important site of sexual HIV 
transmission since it is directly exposed to the penile shaft and HIV-containing seminal fluid 
during vaginal intercourse. The FGM is influenced by many external factors that differs 
between geographical regions, such as STI patterns, and therefore we have included women 
from both Kenya and Sweden. Women who are at high risk of HIV exposure by engaging in 
sexual activities with HIV infected partners have been seen to have a different mucosal 
inflammatory status than low risk women (134). 
The main purpose of this thesis was therefore to investigate how asymptomatic HSV-2 
infection, progesterone-based HC, and long-term risk of sexual HIV exposures affect the 
genital epithelial barrier and the mucosal immune system in order to better understand HIV 
susceptibility factors. A close epidemiological association between HSV-2 and HIV has been 
consistently reported (87), however, there is more to learn about the underlying mechanisms 
of how HSV-2 infection enhances HIV acquisition. Our results show that HSV-2 infection 
may have an impact on the epithelial integrity of the foreskin, and therefore strengthening the 
genital epithelial barrier at the local site could be one way of reducing the risk of HIV 
infection.  
Today, there is an ongoing debate how various progesterone-based hormonal contraceptives 
affect male-to-female HIV transmission. We here extended the knowledge by investigating 
this effect of the ectocervical region in ex vivo studies. Our findings suggested that 
progesterone-based hormonal contraceptive use may have an impact on the ectocervical 
epithelial thickness and integrity which could theoretically enhance HIV susceptibility. 
However, the most common contraceptive method in HIV-endemic Sub-Saharan Africa 
today is the injectable DMPA which contains higher levels of progesterone than the 
progesterone-based HC used in our studies (135). DMPA use has been associated with 
increased HIV susceptibility and HIV shedding in already infected women (95, 97, 136-138), 
and therefore it would be interesting to evaluate its impact in the ectocervical region. Further 
evaluation of the effects of contraceptive use on HIV susceptibility and studies on other FGM 
sites, other study cohorts and other progesterone-based HCs are essential and could guide 
WHO in establishment of adequate guidelines to prevent HIV transmission.  
A number of immunological correlates with the HESN phenotype within the genital mucosa 
have been identified in cervical mononuclear cells and cervicovaginal lavage. However, in 
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this thesis we explored HIV susceptibility factors in unique tissue samples from HESN 
women showing that the HESN phenotype was neither associated with epithelial thickness 
nor with the localization/distribution of HIV target cells. There may be a complex 
multifactorial explanation of the HESN phenotype. Identifying further mucosal immune 
correlates of the HESN phenotype at other sites in the female genital tract including other 
structural and immune markers would be an important step against development towards new 
HIV prevention strategies.  
There is a gap in knowledge in how the initial HIV transmission occur and what factors that 
influence HIV susceptibility at the local site of infection. Our studies hopefully have 
contributed to an increased understanding of the complex dynamics of HIV susceptibility at 
local genital sites. These studies have been possible due to access to unique samples from the 
FGM; the actual site of sexual exposure. Within the female genital tract, we showed 
variations in expression of immune markers in CVS and adjacent tissue illustrating the 
complexity even at the local site. This emphasizes the importance of examining tissue 
specimens in addition to genital secretions to adequately address the effect of factors 
influencing local immune defenses of the FGM. The present projects, and parallel activities in 
our international network, may hopefully lead to deeper insights into the local mucosal milieu 
which is of major importance in order to prevent sexual transmission of HIV. Based on the 
results, it might be possible to identify new ways of strengthening the epithelial barrier by 
topical compounds at the local site, and thereby limit sexual transmission of HIV. 
There are also additional sociological and behavioral aspects strongly affecting the HIV 
epidemic. Therefore, all potential intervention strategies must be implemented by considering 
the affected populations including gender. In Sub-Saharan Africa three in four new HIV 
infections are among girls aged 15–19 years (18). Furthermore, young women in Sub-
Saharan Africa aged 15–24 years are twice as likely to be living with HIV as men which can 
be associated with various social and cultural factors (18). Women are exposed to more 
violence in their relationships, which together with their lower socioeconomic status and 
discrimination cause power imbalance. In some relationships, women often cannot take their 
own decisions about safer sexual practices, including use of contraception (139). In this 
perspective, implementation of antiviral drug administration with topical gels may be 
valuable and may furthermore allow women in taking their own HIV prevention actions. 
Furthermore, this would be of great benefit for FSW, since the HIV prevalence in this key 
population is 13 times higher as compared to the general population (21). In conclusion, 
effective protection of women would have a great impact on the global HIV epidemic and 




6 POPULÄRVETENSKAPLIG SAMMANFATTNING  
 
Idag lever cirka 37 miljoner människor med humant immunbristvirus (HIV) varav de flesta 
lever i södra Afrika. De första fallen av AIDS beskrevs sommaren 1981 och sedan dess har 
över 35 miljoner människor dött till följd av infektionen. Trots 37 års forskning och miljarder 
spenderade dollar är HIV ett virus som fortfarande förbryllar och överlistar världens forskare. 
Det finns idag inget botemedel eller vaccin mot HIV, men sedan mitten av 1990-talet kan 
man bromsa/förhindra utvecklingen av AIDS med effektiva bromsmediciner. Trots detta har 
endast lite mer än hälften av alla som lever med HIV tillgång till bromsmediciner. 
Den vanligaste smittvägen för HIV är oskyddat samlag och för kvinnor verkar 
livmoderhalstappen (ectocervix) vara mottaglig/utsatt för infektion. HIV kan även överföras 
från infekterad moder till barn under graviditet samt vid förlossning och amning, eller via 
annan blodsmitta. Undantaget oskyddat analsex, så är risken att få HIV vid oskyddat samlag 
endast cirka 1:200 vilket troligtvis beror på naturligt skyddande faktorer i slemhinnans 
immunförsvar. Vid oskyddat samlag utsätts vaginala, anala och/eller orala slemhinnorna för 
viruset, varför det är viktigt att forska kring vilka faktorer som kan bidra till ett eventuellt 
skydd mot HIV i dessa slemhinnor. 
För att ta reda på dessa faktorer studeras grupper som är utsatta för HIV men som lyckas 
undgå att bli infekterade (HIV exposed seronegative: HESN), exempelvis prostituerade 
kvinnor i Afrika, för att man tror att framförallt HESN-gruppen har ett naturligt starkare 
försvar mot HIV än andra. Både ärftliga och icke-ärftliga faktorer studeras med 
förhoppningen om att förstå mer exakt hur deras immunförsvar skyddar mot HIV, för att 
sedan kunna använda denna kunskap i framställningen av ett framtida vaccin mot viruset. 
Tidigare studier har visat att det finns faktorer som påverkar hur mottaglig man är för att 
smittas av HIV. Exempelvis har man sett ett samband mellan olika könssjukdomar som till 
exempel herpes typ 2 (HSV-2) och en ökad risk för att bli HIV-infekterad. Även det 
kvinnliga könshormonet progesteron, som ofta ingår i olika typer av preventivmedel, har 
visat sig öka risken för HIV-infektion i ap-modeller. Mekanismerna bakom den ökade risken 
är fortfarande inte kända och återstår att klarläggas. 
Vid en HIV-infektion måste viruset ta sig igenom naturligt förekommande fysiska och 
immunologiska barriärer i vagina. Fysiska barriärer såsom den tjockflytande vätskan 
(sekretet) på slemhinnan och en intakt yttre del på slemhinnan (epitel). Epitelet hålls intakt 
med hjälp av proteiner såsom Claudin, Occludin, E-Cadherin och ZO-1 vilket försvårar för 
viruset att ta sig in. Sekretet innehåller dessutom olika lösliga molekyler såsom 
antimikrobiella peptider (AMPs) som verkar skyddande mot HIV. Om viruset, trots dessa 
skyddsbarriärer, lyckas ta sig igenom kan det binda och infektera dess specifika mål-celler 
CD4+T lymfocyter, dendritiska celler (DCs) och makrofager. För att en infektion av mål-
cellen ska kunna ske, så måste viruset först binda till ett ytprotein, CD4, och sedan även 
ytterligare ett protein CCR5 eller CXCR4. Förutom via dessa proteiner, så kan även DCs och 
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makrofager binda HIV med andra yt-protein så kallade C-type lectin receptorerna (CLRs) 
Langerin, DC-SIGN och Mannose Receptor (MR). Om DC-SIGN binder till viruset så ökar 
risken att smittas eftersom CD4+T cellerna i sin tur infekteras av överfört virus.  
Syftet med denna avhandling var att undersöka hur asymtomatisk HSV-2 infektion, 
progesteron-baserade preventivmedel och exponering för HIV påverkar barriärerna och 
immunsystemet i genitala slemhinnorna, med målet att bättre förstå vilka faktorer som 
påverkar mottagligheten för HIV-infektion. 
Den första studien inkluderade förhudsbiopsier från asymtomatiska HSV-2 positiva och 
HSV-2 negativa män som genomgått omskärelse och resultaten visade att det inte förelåg en 
generell inflammation hos de HSV-2 positiva männen, dock uttryckte de lägre nivåer av 
Claudin-1 vilket skulle kunna tyda på en mindre robust barriär. Ett intakt epitel är nödvändigt 
för att skydda mot sexuellt överförbara infektioner såsom HIV, möjligtvis skulle lägre uttryck 
av Claudin-1 kunna vara en del av förklaringen till att HSV-2 är förknippat med ökad risk för 
HIV.  
I den andra studien undersöktes om användningen av pIUD var associerat med ett tunnare 
epitel, lägre uttryck av proteiner som upprätthåller ett intakt epitel och fördelningen av mål-
celler i ectocervixbiopsier från svenska kvinnor. Resultaten visade att pIUD-gruppen hade ett 
tunnare yttersta epitellager i ectocervix och lägre uttryck av ZO-1 jämfört med 
kontrollgrupperna, även om det inte var någon skillnad gällande uttryck av målceller. Detta 
skulle kunna tyda på att pIUD-användning kan leda till en försvagad barriär mot virus 
inklusive HIV i ectocervix. 
I tredje studien undersöktes huruvida olika hormonella preventivmedel innehållandes 
progesteron påverkar produktionen av AMPs i både vaginala biopsier/sekret från svenska 
kvinnor. Resultaten visade att användandet av dessa preventivmedel påverkade produktionen 
av AMPs på olika sätt i vävnad jämfört med i sekret, vilket tyder på att progesteron påverkar 
lokala immunsvaret på olika sätt beroende på vävnad, sekret och olika lokalisation i vagina. 
I fjärde studien undersöktes huruvida den skyddande HESN-fenotypen är associerad med 
minskning av mål-celler och tjockare skyddande epitel i ectocervixbiopsier från Kenyanska 
prostituerade kvinnor. Resultaten visade ingen skillnad mellan HESN-gruppen och 
kontrollgruppen gällande detta, dock befann sig Langerin-uttryckande celler ytligare i epitelet 
än CD4+CCR5+celler. Resultaten visade inga samband mellan HESN och förändrad 
epiteltjocklek/lokalisation av målceller i ectocervix, men fler studier behövs för att säkerställa 
vilka multifaktoriella, individuella faktorer som möjligen ligger till grund för den skyddande 
fenotypen. 
Sammanfattningsvis, HSV-2 infektion och progesteron-baserade hormonella preventivmedel 
kan påverka genitala slemhinnan och eventuellt öka mottagligheten för HIV.  Progesterons 
påverkan på lokala immunförsvaret är svårt att bedöma eftersom det varierar i olika delar av 
kvinnliga underlivets vävnad och sekret. Vidare har vi inte funnit stöd för att HESN-
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fenotypen är kopplad till tjocklek av epitel eller av HIV-målcellernas lokalisation eller 
mängd, utan sannolikt är det många olika faktorer som bidrar till deras skydd mot HIV.  
Denna avhandling, tillsammans med forskning i vårt internationella nätverk, kommer 
förhoppningsvis leda till en djupare förståelse för de lokala immunologiska mekanismerna i 
genital slemhinna som ger skydd mot HIV. Kanske kan vi i framtiden identifiera nya vägar 
för att stärka slemhinnebarriären genom att ta fram viktiga komponenter som skulle kunna 
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